Nevertheless, in multiple large phase III studies of advanced non-small cell lung cancer, immunotherapy combined with chemotherapy demonstrated superior efficacy compared to PD-(L)1 inhibitor monotherapy, regardless of PD-L1 expression levels. The gene discussed is CD274; the disease is non-small cell lung carcinoma.